Literature DB >> 1904005

Absence of methylthioadenosine phosphorylase in human gliomas.

T Nobori1, J G Karras, F Della Ragione, T A Waltz, P P Chen, D A Carson.   

Abstract

All normal mammalian tissues contain methylthioadenosine phosphorylase, which plays a role in the recycling of purines and methionine consumed during polyamine synthesis. A complete deficiency of methylthioadenosine phosphorylase has been reported in some human leukemias and lymphomas and in a few solid tumors. The exact incidence of the enzyme deficiency among fresh human tumor specimens has been difficult to establish because the measurement of enzyme catalytic activity is laborious and requires carefully preserved specimens. We have generated two antibodies against methylthioadenosine phosphorylase and have used them to develop a simple immunoblot assay for the enzyme. Specifically, studies showed that all cells with catalytically active methylthioadenosine phosphorylase had a 32-kDa band that reacted with the anti-enzyme antibodies. In a reciprocal manner, all malignant cell lines that were naturally deficient in methylthioadenosine phosphorylase activity lacked detectable immunoreactive enzyme protein. The immunoassay was used to analyze human gliomas. Seventy-five % (9 of 12) of the gliomas were completely methylthioadenosine phosphorylase deficient. This common metabolic difference between most gliomas and all normal cells is a potential target for tumor-specific chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904005

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers.

Authors:  T Nobori; K Takabayashi; P Tran; L Orvis; A Batova; A L Yu; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Authors:  Landon J Hansen; Ran Sun; Rui Yang; Simranjit X Singh; Lee H Chen; Christopher J Pirozzi; Casey J Moure; Carlee Hemphill; Austin B Carpenter; Patrick Healy; Ryan C Ruger; Chin-Pu J Chen; Paula K Greer; Fangping Zhao; Ivan Spasojevic; Carole Grenier; Zhiqing Huang; Susan K Murphy; Roger E McLendon; Henry S Friedman; Allan H Friedman; James E Herndon; John H Sampson; Stephen T Keir; Darell D Bigner; Hai Yan; Yiping He
Journal:  Cancer Res       Date:  2019-04-30       Impact factor: 12.701

Review 3.  6-thioguanine: a drug with unrealized potential for cancer therapy.

Authors:  Pashna N Munshi; Martin Lubin; Joseph R Bertino
Journal:  Oncologist       Date:  2014-06-13

4.  Pro-tumorigenic effects of miR-31 loss in mesothelioma.

Authors:  Sergey V Ivanov; Chandra M V Goparaju; Peter Lopez; Jiri Zavadil; Ginat Toren-Haritan; Shai Rosenwald; Moshe Hoshen; Ayelet Chajut; Dalia Cohen; Harvey I Pass
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

Review 5.  Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.

Authors:  Joseph R Bertino; William R Waud; William B Parker; Martin Lubin
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

6.  EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.

Authors:  Ayse Batova; Howard Cottam; John Yu; Mitchell B Diccianni; Carlos J Carrera; Alice L Yu
Journal:  Blood       Date:  2005-10-18       Impact factor: 22.113

7.  A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.

Authors:  Hedy Lee Kindler; Howard A Burris; Alan B Sandler; Ira Anton Oliff
Journal:  Invest New Drugs       Date:  2008-07-11       Impact factor: 3.850

8.  Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation.

Authors:  Kamalakannan Palanichamy; Krishnan Thirumoorthy; Suman Kanji; Nicolaus Gordon; Rajbir Singh; John R Jacob; Nikhil Sebastian; Kevin T Litzenberg; Disha Patel; Emily Bassett; Brinda Ramasubramanian; Tim Lautenschlaeger; Steven M Fischer; Abhik Ray-Chaudhury; Arnab Chakravarti
Journal:  Clin Cancer Res       Date:  2016-03-02       Impact factor: 12.531

9.  Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels.

Authors:  Inês Crespo; Hermínio Tão; Ana Belen Nieto; Olinda Rebelo; Patrícia Domingues; Ana Luísa Vital; Maria del Carmen Patino; Marcos Barbosa; Maria Celeste Lopes; Catarina Resende Oliveira; Alberto Orfao; María Dolores Tabernero
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

Review 10.  Importance of the trans-sulfuration pathway in cancer prevention and promotion.

Authors:  Joemerson Osório Rosado; Mirian Salvador; Diego Bonatto
Journal:  Mol Cell Biochem       Date:  2006-12-16       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.